CyPPA Inhibitor

CyPPA, a positive modulator of SK2 and SK3, reduces the activity of dopaminergic neurons and inhibits dopamine release. CyPPA counteracts hyperdopaminergic behaviors induced by methylphenidate.

Herrik KF, Redrobe JP, Holst D, Hougaard C, Sandager-Nielsen K, Nielsen AN, Ji H, HolstnM, Rasmussen HB, Nielsen Ea˜, Stroba¦k D, Shepard PD, Christophersen P. CyPPA, a Positive SK3/SK2 Modulator, Reduces Activity of Dopaminergic Neurons, Inhibits Dopamine Release, and Counteracts Hyperdopaminergic Behaviors Induced by Methylphenidate. Front Pharmacol. 2012 Feb 13;3:11. doi: 10.3389/fphar.2012.00011. eCollection 2012. PubMed PMID: 22347859; PubMed Central PMCID: PMC3278045.
Dolga AM, Letsche T, Gold M, Doti N, Bacher M, Chiamvimonvat N, Dodel R, Culmsee C. Activation of KCNN3/SK3/K(Ca)2.3 channels attenuates enhanced calcium influx and inflammatory cytokine production in activated microglia. Glia. 2012 Dec;60(12):2050-64. doi: 10.1002/glia.22419. Epub 2012 Sep 21. PubMed PMID: 23002008; PubMed Central PMCID: PMC3799773.

Small volumes of CyPPA, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS5756602 is an inhibitor targeting CyPPA.